AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations

AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations

Source: 
BioSpace
snippet: 

AstraZeneca and Merck released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). Specifically, in patients who have a homologous recombination repair gene mutation (HRRm) and have progressed despite previous treatment with new hormonal agent (NHA) treatments such as enzalutamide and abiraterone.